SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Shionogi & Co., Ltd. SGIOF OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • JP • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Shionogi & Co., Ltd. (SGIOF) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $21.85. It has a SharesGrow Score of 91/100, indicating a strong investment profile with 6 out of 7 criteria passed.

Financials: revenue is $438.3B, +10%/yr average growth. Net income is $170.4B, growing at +18.3%/yr. Net profit margin is 38.9% (strong). Gross margin is 85.4% (+1.9 pp trend).

Balance sheet: total debt is $21.9B against $1.4T equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 6.63 (strong liquidity). Debt-to-assets is 1.4%. Total assets: $1.5T.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 80/100 (Pass), Past 100/100 (Pass), Health 100/100 (Pass), Moat 84/100 (Pass), Future ?/100 (Fail), Income 100/100 (Pass).

SGIOF SharesGrow Score Overview

94/100

SharesGrow Score

Strong investment profile

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 80/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 84/100

Gross margin is + market cap

FUTURE 0/100

Analyst outlook — as buy

INCOME 100/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SGIOF

SGIOF trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

SGIOF: +10%/yr revenue is, +18.3%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

SGIOF: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet SGIOF: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 6.63 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

SGIOF: Gross margin is 85.4% (+1.9 pp trend), $19B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 84/100. ≥ 70 = Pass.

View details →

No analyst coverage available for this stock.

SGIOF: Net profit margin is 38.9%. strong (≥30%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range14.25-26

Volume256

Avg Volume (30D)131

Market Cap$18.59B

Beta (1Y)0.08

Dividend Yield$0.4200

Share Statistics

EPS (TTM)600.98

Shares Outstanding$283.6M

IPO Date2018-02-28

Employees4,955

CEOIsao Teshirogi

Financial Highlights & Ratios

Revenue (TTM)$438.27B

Gross Profit$374.44B

EBITDA$230.71B

Net Income$170.44B

Operating Income$156.6B

Total Cash$644.82B

Total Debt$21.88B

Net Debt$-352.91B

Total Assets$1.54T

Price / Earnings (P/E)0

Price / Sales (P/S)0.04

Analyst Forecast

Company Info

CountryJP

ExchangeOther OTC

CurrencyUSD

ISINJP3347200002

Price Chart

SGIOF

Shionogi & Co., Ltd. ↗ · Other OTC

Healthcare • Drug Manufacturers - Specialty & Generic

14.25 52WK RANGE 26.00

People Also View

Taisho Pharmaceutical Holdings Co., Ltd.

Shionogi & Co., Ltd.

Neurocrine Biosciences, Inc.

Deciphera Pharmaceuticals, Inc.

Curaleaf Holdings, Inc.

Trulieve Cannabis Corp.

Pacira BioSciences, Inc.

Ironwood Pharmaceuticals, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message